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Glucose-responsive insulin secretion is frequently impaired prior to the onset 
of type 2 diabetes [1]. In addition, considering the reduced pancreatic beta cell 
mass in patients with type 2 diabetes [2], defects in insulin secretion appear 
heterogeneous in this patient group. In some patients, only postprandial 
insulin secretion appears impaired, whilst in others, basal insulin secretion is 
also affected. However, postprandial insulin secretion is impaired in almost 
all patients with type 2 diabetes.  
     In the recently published consensus statement from the American 
Diabetes Association [3] and the European Association for the Study of 
Diabetes [4] concerning the initiation and adjustment of therapy for managing 
hyperglycaemia in type 2 diabetes, initial insulin therapy is aimed at 
increasing basal insulin supply with intermediate- or long-acting insulins. Such 
a regimen cannot completely mimic a physiological pattern of insulin secretion. 
Consequently, postprandial glycaemic control tends to be inadequate, and a 
risk exists of fasting hypoglycaemia. Furthermore, the postprandial 
hyperglycaemia observed in patients with early-stage or mild type 2 diabetes 
increased the risk of microangiopathy or arteriosclerosis in two large-scale 
clinical studies of type 2 diabetes, the United Kingdom Prospective Diabetes 
Study [5] and the DECODE study [6]. It has also been suggested that therapy 
focussed on lowering postprandial glucose, rather than fasting glucose, may be 
superior for lowering HbA1c [7] and glucose variability (spike) [8]. Insulin 
preparations have been developed to provide insulin replacement that more 
closely reflects physiological insulin secretion; the introduction of rapid-acting 
insulin analogues and long-acting soluble insulin analogues has been a further 
step in this direction. Rapid-acting insulin analogues have been particularly 
effective at targeting postprandial hyperglycaemia [8]. They can, therefore, 
effectively reduce postprandial plasma glucose, even if administered 
immediately before a meal, and also minimise the risk of hypoglycaemia prior 
to the next meal [8]. 
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     The exact contribution of postprandial and fasting glucose increments to 
overall hyperglycaemia remains controversial. Monnier and colleagues 
reported that postprandial glucose excursion contributes up to ~70% of the 
glucose load in patients with diabetes whose HbA1c levels are <7.3%, whereas 
the contribution of fasting hyperglycaemia increases gradually as diabetes 
worsens [9]. However, even in patients whose glycaemic control is poor, 
studies have demonstrated that treatment targeting postprandial 
hyperglycaemia, which improves glucose-responsive insulin secretion in 
patients with glucose desensitisation, improves both postprandial and also 
morning fasting plasma glucose (FPG) in such patients [10–12].  
We hypothesised that mealtime dosing with rapid-acting insulin analogues 
strictly controls postprandial and daytime plasma glucose levels, and thereby 
improves glucose desensitisation and glucose-responsive insulin secretion. To 
test these hypotheses, we recently evaluated the effect of a mealtime, 
rapid-acting insulin analogue on the minimum early morning FPG levels 
(nadir FPG) in 40 Japanese patients with type 2 diabetes whose existing 
antidiabetic medication was discontinued [12]. Approximately half (52.5%) of 
the patients achieved a nadir FPG of <6.7 mmol/l with mealtime dosing of a 
rapid-acting insulin analogue alone. No basal insulin replacement was needed 
in these patients. Patients, on the other hand, whose FPG levels remained 
high, even after postprandial hyperglycaemia improved, were presumed to 
have defects in basal insulin secretion [12]. To further confirm our finding, we 
prospectively followed 160 patients with type 2 diabetes treated with 
mealtime dosing of a rapid-acting insulin analogue. After 1 year of treatment 
at our out-patient clinic, about 60% of these patients were able to continue 
this therapy successfully; FPG was 6.4±1.6 mmol/l and HbA1c was 6.5±1.1%, 
compared with FPG of 6.0±1.2 mmol/l and HbA1c of 6.9±1.1% in the patients 
who required additional basal insulin replacement (Takamura et al., 
unpublished observation). This suggests that basal insulin secretion was 
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maintained in these patients, and only prandial insulin secretion was 
impaired. For such patients, glycaemic control achieved with sulfonylureas, 
which continuously promote insulin secretion, or with a long-acting insulin, 
may increase the risk of fasting hypoglycaemia. It may also contribute to 
obesity as a result of differentiation or hyperplasia of adipocytes during 
episodes of hyperinsulinaemia. Such patients may benefit instead from 
treatment with rapid-acting insulin analogue preparations, which more 
closely mimic physiological insulin secretion. These formulations may reduce 
the risk of hypoglycaemia by achieving a better balance between glucose and 
insulin levels, and also minimise increases in obesity, which might otherwise 
result from persistent hyperinsulinaemia during periods of fasting or after 
meals.  
Based on these findings, we propose mealtime dosing with a rapid-acting 
insulin analogue as an initial insulin regimen for patients with type 2 
diabetes. This regimen may be superior in lowering postprandial glucose 
excursion and the glucose spike, which are cardiovascular risk factors. The 
regimen may also help reduce the risk of hypoglycaemia and obesity 
associated with insulin therapy. Because not only postprandial, but also FPG 
can be modestly reduced by this regimen, the requirement for basal insulin 
replacement should be considered only in patients who do not achieve good 
FPG levels thereafter.  
We suggest that further discussion is needed for better care of patients with 
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